Literature DB >> 31907423

Breast cancer drug approvals by the US FDA from 1949 to 2018.

Chandra P Leo, Cornelia Leo, Thomas D Szucs.   

Abstract

Entities:  

Year:  2020        PMID： 31907423     DOI： 10.1038/d41573-019-00201-w

Source DB:  PubMed          Journal:  Nat Rev Drug Discov        ISSN： 1474-1776            Impact factor:   84.694


× No keyword cloud information.
  9 in total

Review 1.  Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021.

Authors:  Qing Wu; Wei Qian; Xiaoli Sun; Shaojie Jiang
Journal:  J Hematol Oncol       Date:  2022-10-08       Impact factor: 23.168

2.  T-DM1 after Pertuzumab plus Trastuzumab: Treatment Sequence-Induced Selection Bias in HER2-Positive Metastatic Breast Cancer.

Authors:  Thibaut Sanglier; Alessandra Fabi; Carlos Flores; Evelyn M Flahavan; Claudia Pena-Murillo; Anne-Marie Meyer; Filippo Montemurro
Journal:  Cancers (Basel)       Date:  2022-05-17       Impact factor: 6.575

Review 3.  Estrogen Receptor Bio-Activities Determine Clinical Endocrine Treatment Options in Estrogen Receptor-Positive Breast Cancer.

Authors:  Song Xia; Qiong Lin
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

4.  Development of Gene Expression-Based Random Forest Model for Predicting Neoadjuvant Chemotherapy Response in Triple-Negative Breast Cancer.

Authors:  Seongyong Park; Gwansu Yi
Journal:  Cancers (Basel)       Date:  2022-02-10       Impact factor: 6.639

5.  High-Throughput Tumor-on-a-Chip Platform to Study Tumor-Stroma Interactions and Drug Pharmacokinetics.

Authors:  Chun-Wei Chi; Yeh-Hsing Lao; A H Rezwanuddin Ahmed; Elizabeth C Benoy; Chenghai Li; Zeynep Dereli-Korkut; Bingmei M Fu; Kam W Leong; Sihong Wang
Journal:  Adv Healthc Mater       Date:  2020-09-23       Impact factor: 9.933

6.  An UHPLC-MS/MS method for quantification of the CDK4/6 inhibitor abemaciclib in human serum.

Authors:  Katharina Habler; Michael Vogeser; Daniel Teupser
Journal:  J Mass Spectrom Adv Clin Lab       Date:  2022-02-07

Review 7.  Reciprocal Regulation of Hippo and WBP2 Signalling-Implications in Cancer Therapy.

Authors:  Yvonne Xinyi Lim; Hexian Lin; Sock Hong Seah; Yoon Pin Lim
Journal:  Cells       Date:  2021-11-11       Impact factor: 6.600

Review 8.  Engineering Breast Cancer On-chip-Moving Toward Subtype Specific Models.

Authors:  Carmen Moccia; Kristina Haase
Journal:  Front Bioeng Biotechnol       Date:  2021-06-23

Review 9.  The Fight against Cancer by Microgravity: The Multicellular Spheroid as a Metastasis Model.

Authors:  Daniela Grimm; Herbert Schulz; Marcus Krüger; José Luis Cortés-Sánchez; Marcel Egli; Armin Kraus; Jayashree Sahana; Thomas J Corydon; Ruth Hemmersbach; Petra M Wise; Manfred Infanger; Markus Wehland
Journal:  Int J Mol Sci       Date:  2022-03-12       Impact factor: 5.923
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.